Analytical Sciences, BioPharmaceuticals Development, R&D, AstraZeneca, Gaithersburg, MD, United States of America.
PLoS One. 2020 Jul 28;15(7):e0236740. doi: 10.1371/journal.pone.0236740. eCollection 2020.
Tryptic digestion of proteins followed by liquid chromatography with tandem mass spectrometry analysis is an extensively used approach in proteomics research and biopharmaceutical product characterization, owing to the high level of cleavage fidelity produced with this technique. However, nonspecific trypsin cleavages have been frequently reported and shown to be related to a number of digestion conditions and predigestion sample treatments. In this work, we reveal that, for a number of commercial trypsins, reconstitution and storage conditions can have a significant impact on the occurrence of trypsin nonspecific cleavages. We analyzed the tryptic digestion of a variety of biotherapeutics, using trypsins reconstituted under different conditions. The results indicate that, for many commercial trypsins, commonly recommended reconstitution/storage conditions (mildly acidic, e.g., 50 mM acetic acid, 1 mM HCl) can actually promote nonspecific trypsin activities, which are time dependent and can be as high as 20% in total relative abundance. In contrast, using water for reconstitution and storage can effectively limit nonspecific cleavages to 1%. Interestingly, the performances of different commercial trypsins were found to be quite distinct in their levels of nonspecific cleavages and responses to the two reconstitution conditions. Our findings demonstrate the importance of choosing the appropriate trypsin for tryptic digestion and the necessity of assessing the impact of trypsin reconstitution and storage on nonspecific cleavages. We advocate for manufacturers of commercial trypsins to reevaluate manufacturing processes and reconstitution/storage conditions to provide good cleavage specificity.
蛋白质的酶切消化后进行液相色谱-串联质谱分析,是蛋白质组学研究和生物制药产品特性分析中广泛应用的方法,因为这种技术可以产生高度准确的酶切结果。然而,非特异性胰蛋白酶切割已被频繁报道,并被证明与许多消化条件和预消化样品处理有关。在这项工作中,我们揭示了对于许多商业胰蛋白酶,其再构成和储存条件会对胰蛋白酶非特异性切割的发生产生重大影响。我们分析了使用不同条件再构成的胰蛋白酶对各种生物治疗药物的酶切消化。结果表明,对于许多商业胰蛋白酶,通常推荐的再构成/储存条件(微酸性,例如 50mM 乙酸、1mM HCl)实际上可以促进非特异性胰蛋白酶活性,这种活性是时间依赖性的,在总相对丰度中可以高达 20%。相比之下,使用水进行再构成和储存可以有效地将非特异性切割限制在 1%。有趣的是,不同商业胰蛋白酶的性能在非特异性切割水平和对两种再构成条件的反应方面存在明显差异。我们的研究结果表明,选择适当的胰蛋白酶进行酶切消化非常重要,并且需要评估胰蛋白酶再构成和储存对非特异性切割的影响。我们主张商业胰蛋白酶制造商重新评估制造工艺和再构成/储存条件,以提供良好的切割特异性。